Form 4: Adagio Medical Holdings Director Acquires 90,000 Stock Options

Director Timothy P. Moran reports acquisition of 90,000 non-qualified stock options in Adagio Medical Holdings, Inc.

Summary

• Timothy P. Moran, a director of Adagio Medical Holdings, Inc., filed a Form 4 disclosing a transaction involving the acquisition of derivative securities.
• On March 20, 2025, Moran acquired 90,000 non-qualified stock options with an exercise price of $0.865.
• These options were granted under the Issuer's 2024 Equity Incentive Plan and approved by the Compensation Committee on the same date.
• The options vest monthly over a three-year period, starting July 31, 2024, with 1/36th of the shares vesting each month of continuous service.
• The options expire on July 31, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant, which is neither inherently positive nor negative.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the medical device industry to incentivize executives and align their interests with shareholders. This filing is a routine disclosure of such a grant.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the medical device industry.
• Companies like Medtronic, Boston Scientific, and Abbott also utilize stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for long-term value creation.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It incentivizes the director to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, stock options, Adagio Medical Holdings, derivative securities, insider trading, equity incentive plan, director, ADGM